- Home
- CLYM vs CVRX Comparison
CLYM vs CVRX Comparison
Compare CLYM & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- CVRX
- Stock Information
- Founded
- CLYM 2018
- CVRX 2000
- Country
- CLYM United States
- CVRX United States
- Employees
- CLYM N/A
- CVRX N/A
- Industry
- CLYM
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CLYM
- CVRX Health Care
- Exchange
- CLYM NYSE
- CVRX Nasdaq
- Market Cap
- CLYM 242.8M
- CVRX 206.7M
- IPO Year
- CLYM 2021
- CVRX 2021
- Fundamental
- Price
- CLYM $3.79
- CVRX $15.74
- Analyst Decision
- CLYM
- CVRX Buy
- Analyst Count
- CLYM 0
- CVRX 7
- Target Price
- CLYM N/A
- CVRX $15.83
- AVG Volume (30 Days)
- CLYM 331.1K
- CVRX 494.0K
- Earning Date
- CLYM 11-22-2024
- CVRX 10-29-2024
- Dividend Yield
- CLYM N/A
- CVRX N/A
- EPS Growth
- CLYM N/A
- CVRX N/A
- EPS
- CLYM N/A
- CVRX N/A
- Revenue
- CLYM N/A
- CVRX $47,255,000.00
- Revenue This Year
- CLYM N/A
- CVRX $31.78
- Revenue Next Year
- CLYM N/A
- CVRX $26.70
- P/E Ratio
- CLYM N/A
- CVRX N/A
- Revenue Growth
- CLYM N/A
- CVRX 34.38
- 52 Week Low
- CLYM $2.35
- CVRX $6.40
- 52 Week High
- CLYM $11.55
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- CVRX 79.56
- Support Level
- CLYM N/A
- CVRX $15.38
- Resistance Level
- CLYM N/A
- CVRX $15.95
- Average True Range (ATR)
- CLYM 0.00
- CVRX 1.00
- MACD
- CLYM 0.00
- CVRX 0.34
- Stochastic Oscillator
- CLYM 0.00
- CVRX 96.53
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.